Associated Genetic Biomarkers

Overview

NCI Definition: A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement. [1]

Chronic myelomonocytic leukemias most frequently harbor alterations in TET2, SRSF2, ASXL1, NRAS, and CBL [2].

Most Commonly Altered Genes in Chronic Myelomonocytic Leukemia

SRSF2 Mutation, SRSF2 Exon 1 Mutation, TET2 Mutation, SRSF2 Codon 95 Missense, and ASXL1fs are the most common alterations in chronic myelomonocytic leukemia [2].

Top Alterations in Chronic Myelomonocytic Leukemia

Significant Genes in Chronic Myelomonocytic Leukemia

ABL1 +

ABL2 +

AFF1 +

ARAF +

ASXL1 +

BCOR +

BCR +

BRAF +

CBFB +

CBL +

CRKL +

CRLF2 +

DEK +

DNMT3A +

ELL +

EPOR +

EZH2 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT3 +

HRAS +

IDH1 +

IDH2 +

IGH +

IL7R +

JAK1 +

JAK2 +

JAK3 +

KIT +

KMT2A +

KRAS +

LYN +

MAF +

MAFB +

MAP2K1 +

MAP2K2 +

MAP2K4 +

MAP3K1 +

MAPK1 +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYH11 +

NF1 +

NPM1 +

NRAS +

NRIP3 +

NTRK1 +

NTRK2 +

NTRK3 +

NUP214 +

PBX1 +

PDGFRA +

PDGFRB +

PHF6 +

PML +

PTPN11 +

RAF1 +

RARA +

RIT1 +

RPN1 +

RUNX1 +

RUNX1T1 +

SETBP1 +

SF3B1 +

SH2B3 +

SRC +

SRSF2 +

STAG2 +

TCF3 +

TET2 +

TP53 +

TYK2 +

U2AF1 +

WHSC1 +

ZRSR2 +

Disease Details

Synonyms
Bone marrow leukemia non-lymphocytic myelomonocytic (MML), CMML
Parent(s)
Myelodysplastic/Myeloproliferative Neoplasm
Children
Chronic Myelomonocytic Leukemia-2, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-0, and Therapy-Related Chronic Myelomonocytic Leukemia
OncoTree Name
Chronic Myelomonocytic Leukemia
OncoTree Code
CMML

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.